Effects of two inhaled corticosteroid/long-acting beta-agonist combinations on small-airway dysfunction in mild asthmatics measured by impulse oscillometry

Figures & data

Figure 1 t-test P-values of impulse oscillometry parameters (frequency-dependent resistance [R5–R20], * and reactance [AX], ■) at each time point after administration of Advair or Symbicort during randomization visits compared to the patients’ baseline R5–R20 and AX values (0.204 cmH₂O/L/second and 1.526 cmH₂O/L, respectively, for Advair; 0.259 cmH₂O/L/second, and 2.332 cmH₂O/L, respectively, for Symbicort) during the same visit (n = 15 for each group).

Figure 2 t-test P-values of impulse oscillometry parameters (frequency-dependent resistance [R5–R20], * and reactance [AX], ■) at each time point after administration of Advair or Symbicort during final visits compared to the patients’ baseline R5–R20 and AX values (0.164 cmH₂O/L/second and 1.171 cmH₂O/L, respectively, for Advair; 0.127 cmH₂O/L/second and 0.833 cmH₂O/L, respectively, for Symbicort) during the same visit (n = 15 for each group).

Figure 3 t-test P-values of model estimates (peripheral airway resistance [R_p], ■; peripheral airway compliance [C_p], ×) at each time point after administration of Advair or Symbicort during randomization visits compared to the patients’ baseline R_p and C_p values (0.547 cmH₂O/L/second and 0.084 L/cmH₂O, respectively, for Advair; 0.689 cmH₂O/L/second and 0.067 L/cmH₂O, respectively, for Symbicort) during the same visit (n = 15 for each group).

Figure 4 t-test P-values of model estimates (peripheral airway resistance [R_p], ■; peripheral airway compliance [C_p], ×) at each time point after administration of Advair or Symbicort during final visits compared to the patients’ baseline R_p and C_p values (0.472 cmH₂O/L/second and 0.115 L/cmH₂O, respectively, for Advair; 0.426 cmH₂O/L/second and 0.136 L/cmH₂O, respectively, for Symbicort) during the same visit (n = 15 for each group).

Table 1 Mean values of impulse oscillometry system frequency-dependent resistance (R5–R20; cmH₂O/L/s) and reactance AX (cmH₂O/L), peripheral airway resistance (R_p; cmH₂O/L/s), and peripheral airway compliance (C_p; L/cmH₂O) at baseline (BL) and each time point after administration of Advair or Symbicort during the randomization and final visits

	Advair (randomization visit)							Symbicort (randomization visit)
	BL	5	20	40	60	120	240	BL	5	20	40	60	120	240
R5–R20	0.204	0.159	0.126	0.114	0.113	0.127	0.129	0.259	0.113	0.108	0.112	0.097	0.096	0.098
AX	1.526	1.122	0.774	0.692	0.660	0.759	0.763	2.332	0.643	0.597	0.663	0.554	0.537	0.536
Rp	0.547	0.503	0.423	0.425	0.396	0.409	0.394	0.689	0.397	0.380	0.403	0.372	0.356	0.359
Cp	0.084	0.114	0.138	0.141	0.146	0.135	0.139	0.067	0.134	0.161	0.143	0.152	0.162	0.163
	Advair (final visit)							Symbicort (final visit)
	BL	5	20	40	60	120	240	BL	5	20	40	60	120	240
R5–R20	0.164	0.135	0.119	0.111	0.118	0.118	0.123	0.127	0.101	0.094	0.099	0.099	0.096	0.096
AX	1.171	0.841	0.663	0.613	0.594	0.606	0.687	0.833	0.571	0.551	0.554	0.545	0.526	0.529
Rp	0.472	0.429	0.406	0.387	0.372	0.361	0.405	0.426	0.406	0.399	0.385	0.370	0.350	0.364
Cp	0.115	0.130	0.141	0.150	0.147	0.147	0.139	0.136	0.166	0.165	0.161	0.163	0.168	0.169

Figure 5 Box plots of the individual impulse oscillometry frequency-dependent reactance (AX) values at two time points each during the randomization visits (VR) and the final visits (VF) for (A) the Advair group and (B) the Symbicort group.(/p)(p)Abbreviation: BL, baseline.

Figure 6 Box plots of the individual impulse oscillometry frequency-dependent resistance (R5–R20) values at two time points each during the randomization visits (VR) and the final visits (VF) for (A) the Advair group and (B) the Symbicort group.(/p)(p)Abbreviation: BL, baseline.

Figure 7 Box plots of the individual peripheral airway compliance (C_p) values at two time points each during the randomization visits (VR) and the final visits (VF) for (A) the Advair group and (B) the Symbicort group.(/p)(p)Abbreviation: BL, baseline.

Figure 8 Box plots of the individual peripheral airway resistance (R_p) values at two time points each during the randomization visits (VR) and the final visits (VF) for (A) the Advair group and (B) the Symbicort group.(/p)(p)Abbreviation: BL, baseline.

Figure 9 Mean forced expiratory volume in 1 second (FEV₁) during the first 180 minutes after inhalation of budesonide/formoterol (pressurized metered-dose inhaler [pMDI] 2 × 160/4.5 mg), salmeterol/fluticasone (pMDI 2 × 25/250 mg), salbutamol (2 × 100 mg), or placebo (percentage increase from predrug value). Copyright © 2001, Elsevier. Palmqvist M, Arvidsson P, Beckman O, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs salmeterol/fluticasone in single inhalers. Pulm Pharmacol Ther. 2001;14(1):29–34.²

Figure 10 Percent change in forced expiratory volume in 1 second (FEV₁) up to 15 minutes and 3 hours with the combination of budesonide/formoterol (one or two inhalations) (160/4.5 mg) compared with the combination salmeterol/fluticasone (50/250 mg) and placebo. Reprinted from Lindberg et al,¹⁰ with permission from John Wiley and Sons.

PalmqvistMArvidssonPBeckmanOPetersonSLötvallJOnset of bronchodilation of budesonide/formoterol vs salmeterol/fluticasone in single inhalersPulm Pharmacol Ther2001141293411162416

 PubMed Web of Science ®Google Scholar

LindbergASzalaiZPulleritsTRadeczkyEFast onset of effect of budesonide/formoterol versus salmeterol/fluticasone and salbutamol in patients with chronic obstructive pulmonary disease and reversible airway obstructionRespirology200712573273917875063

 PubMed Web of Science ®Google Scholar